Polyhalogenated aromatic hydrocarbons (PHAHs), such as polychlorinated dibenzo-p-dioxins and dibenzofurans, polybrominated diphenylethers, and bisphenol A derivatives are persistent environmental pollutants, which are capable of interfering with reproductive and endocrine function in birds, fish, reptiles, and mammals. PHAHs exert estrogenic effects that may be mediated in part by their hydroxylated metabolites (PHAH-OHs), the mechanisms of which remain to be identified. PHAH-OHs show low affinity for the ER. Alternatively, they may exert their estrogenic effects by inhibiting E2 metabolism. As sulfation of E2 by estrogen sulfotransferase (SULT1E1) is an important pathway for E2 inactivation, inhibition of SULT1E1 may lead to an increased bioavailability of estrogens in tissues expressing this enzyme. Therefore, we studied the possible inhibition of human SULT1E1 by hydroxylated PHAH metabolites and the sulfation of the different compounds by SULT1E1. We found marked inhibition of SULT1E1 by various PHAH-OHs, in particular by compounds with two adjacent halogen substituents around the hydroxyl group that were effective at (sub)nanomolar concentrations. Depending on the structure, the inhibition is primarily competitive or noncompetitive. Most PHAH-OHs are also sulfated by SULT1E1. We also investigated the inhibitory effects of the various PHAH-OHs on E2 sulfation by human liver cytosol and found that the effects were strongly correlated with their inhibitions of recombinant SULT1E1 (r ‫؍‬ 0.922). Based on these results, we hypothesize that hydroxylated PHAHs exert their estrogenic effects at least in part by inhibiting SULT1E1-catalyzed E2 sulfation. (J Clin Endocrinol
Polyhalogenated aromatic hydrocarbons (PHAHs), such as polychlorinated dibenzo-p-dioxins and dibenzofurans, polybrominated diphenylethers, and bisphenol A derivatives are persistent environmental pollutants, which are capable of interfering with reproductive and endocrine function in birds, fish, reptiles, and mammals. PHAHs exert estrogenic effects that may be mediated in part by their hydroxylated metabolites (PHAH-OHs), the mechanisms of which remain to be identified. PHAH-OHs show low affinity for the ER. Alternatively, they may exert their estrogenic effects by inhibiting E2 metabolism. As sulfation of E2 by estrogen sulfotransferase (SULT1E1) is an important pathway for E2 inactivation, inhibition of SULT1E1 may lead to an increased bioavailability of estrogens in tissues expressing this enzyme. Therefore, we studied the possible inhibition of human SULT1E1 by hydroxylated PHAH metabolites and the sulfation of the different compounds by SULT1E1. We found marked inhibition of SULT1E1 by various PHAH-OHs, in particular by compounds with two adjacent halogen substituents around the hydroxyl group that were effective at (sub)nanomolar concentrations. Depending on the structure, the inhibition is primarily competitive or noncompetitive. Most PHAH-OHs are also sulfated by SULT1E1. We also investigated the inhibitory effects of the various PHAH-OHs on E2 sulfation by human liver cytosol and found that the effects were strongly correlated with their inhibitions of recombinant SULT1E1 (r ‫؍‬ 0.922). Based on these results, we hypothesize that hydroxylated PHAHs exert their estrogenic effects at least in part by inhibiting SULT1E1-catalyzed E2 sulfation. (J Clin Endocrinol Metab 87: 1142-1150, 2002) R ECENTLY, MANY STUDIES have been performed on the interaction of environmental chemicals with the endocrine system, which results in reproductive and developmental anomalies in various organisms (1) (2) (3) (4) . Endocrinedisrupting effects have been observed in adult animals that were exposed in utero to polyhalogenated aromatic hydrocarbons (PHAHs) such as polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and polychlorinated biphenyls (PCBs) (5-7). Hilakivi-Clarke et al. (8) demonstrated in rats that exposure to natural estrogens in utero advanced puberty onset and increased breast cancer risk in the offspring; this may also apply to environmental estrogens. In humans, abnormalities in the development of the reproductive tract, reduced sperm counts (3, 9) , and increased incidence of germ cell cancer (10) have been related to exposure to endocrine disrupters present in the environment. Furthermore, several studies have reported increased levels of PCBs, 2,2-bis-(4-chlorophenyl)-1,1,1-trichloroethane and its metabolite 2,2-bis-(4-chlorophenyl)-1,1-dichloroethylene in breast cancer patients (11, 12) . However, recent epidemiological research does not support the hypothesis that women exposed to organochlorines such as PCBs, PCDDs, 2,2-bis-(4-chlorophenyl)-1,1,1-trichloroethane, and 2,2-bis-(4-chlorophenyl)-1,1-dichloroethylene have an increased breast cancer risk (13) (14) (15) .
Hydroxylated metabolites of the PHAHs (PHAH-OHs) may contribute to the aforementioned effects. Hydroxylated metabolites of PCBs (PCB-OHs), PCDDs (PCDD-OHs), and PCDFs (PCDF-OHs) and other organohalogens have been identified in blood, bile, and urine of animals treated with the parent compound, but also in wildlife samples as well as in environmentally exposed human subjects (16 -20) . Hydroxylation of PCDDs and PCDFs in mammals preferentially occurs on the lateral (2, 3, 7, 8) positions (18 -20) . For PCBs, it has been determined that hydroxylated metabolites are partially responsible for the endocrine-disrupting effects. For instance, Crews et al. (21) showed that different hydroxylated PCBs altered the sexual differentiation of the turtle.
The mechanisms by which PHAH-OHs exert their estrogenic effects are still not understood. Binding affinities for ER␣ and ER␤ are relatively low (22, 23) . It is possible, however, that PHAH-OHs exert part of their estrogenic effects by increasing the bioavailability of E2 through inhibition of E2 inactivation in target tissues. Sulfation by the specific estrogen sulfotransferase SULT1E1 is an important pathway for the inactivation of E2 (24) . The human enzyme has a low K m value of 4 nm for E2 and is expressed in target tissues such as the endometrium, mammary gland, and testis as well as in the liver (25) (26) (27) (28) (29) . Recently, we demonstrated potent inhibition of SULT1E1 by hydroxylated PCB metabolites (30) , in particular compounds with two adjacent chlorine substituents around the hydroxyl group. Here, we have investigated the potency and type of inhibition of human SULT1E1 by other important PHAH-OHs, such as PCDD-OHs, PCDFOHs, and hydroxylated polybromodiphenylethers (PBDEOHs), and by halogenated bisphenol A (BPA) derivatives as well as their sulfation by SULT1E1. To determine the relevance of our findings using recombinant enzyme, we also studied the inhibition of E2 sulfation by native SULT1E1 in human liver cytosol (29) . Furthermore, we analyzed the sulfation of the various PHAH-OHs by SULT1E1 and SULT1A1, another phenol sulfotransferase abundantly expressed in human liver (31, 32) .
Materials and Methods Materials
E2 and 3Ј-phosphoadenosine-5Ј-phosphosulfate (PAPS) were obtained from Sigma (St. Louis, MO), [ 3 H]E2 (3.22 MBq/nmol) was obtained from Amersham Pharmacia Biotech (Little Chalfont, UK), and [ 35 S]PAPS (52.9 MBq/mol) was purchased from NEN Life Science Products (Boston, MA). The sources of the various hydroxylated organohalogens have been described previously (23, 33, 34) . Human SULT1E1 (35) and SULT1A1 (31) were expressed in Salmonella typhimurium as previously described (36, 37) . Cytosolic fractions were prepared and used without further purification (36, 37) . SULT1E1 accounted for 5-7% of the cytosolic proteins. Similar results were obtained using recombinant SULT1E1 expressed in Escherichia coli and purified as previously described (38) . Normal human liver was obtained at surgical resection of liver tumors, and cytosol was prepared as previously described (39) . Approval was obtained from the medical ethical committee of Erasmus University Medical Center.
Estrogen sulfotransferase assay
Estrogen sulfotransferase activity was analyzed by measuring the formation of water-soluble [ 3 H]E2 sulfate after incubation of 1 nm [ 3 H]E2 for 30 min at 37 C with recombinant SULT1E1 (0.1 g total cytosolic protein/ml) in the presence or absence (blanks) of 50 m of the cofactor PAPS in 0.2 ml 0.1 m sodium phosphate (pH 7.2), 2 mm EDTA, and 1 mm dithiothreitol. The reactions were stopped by the addition of 2 ml icecold water, and unreacted [ 3 H]E2 was removed by extraction with 2 ml dichloromethane. Sulfate formation was quantified by liquid scintillation counting of 1 ml of the aqueous phase. Enzymatic sulfation was corrected for background radioactivity estimated in the blanks. Inhibition of E2 sulfation by PHAH-OHs was assessed by addition of 0.01 nm to 10 m of these compounds to the reaction mixtures. Kinetic parameters for E2 sulfation were determined by Lineweaver-Burk analysis (40) of the sulfation of varying substrate concentrations. Apparent K i values for inhibitors were calculated from the change in slope of the Lineweaver-Burk plot in the presence of a fixed inhibitor concentration (40) .
Sulfation of PHAH-OHs
The above assay of estrogen sulfotransferase activity is based on the sulfation of limited concentrations of radioactive E2 by excess unlabeled PAPS. As radioactive PHAH-OHs are not available, their sulfation was analyzed in comparison with E2 by determining the transfer of 35 The presumably soluble sulfated products were quantified by liquid scintillation counting of 500 l of the supernatant. Sulfation was corrected for background radioactivity determined in blanks without substrate. For HPLC analysis, the reactions were stopped by the addition of 150 l ice-cold methanol. After centrifugation, 100 l of the supernatant were injected onto a 4.6 ϫ 250-mm Symmetry C 18 column connected to an Alliance HPLC system (Waters Chromatography BV, Etten-Leur, The Netherlands), and eluted with a gradient of acetonitrile in 50 mm triethyl ammonium acetate (pH 6.8) at a flow of 1.0 ml/min. The proportion of acetonitrile was increased linearly from 35% to 65% in 15 min and further to 90% in an additional 10 min. The radioactivity in the eluate was determined using a Radiomatic A-500 flow scintillation detector (Packard, Meriden, CT).
Results
The effects of 0.01 nm to 10 m of different classes of PHAH-OHs on the sulfation of 1 nm E2 by SULT1E1 were tested. Table 1 Figure 1 shows the results with PCDD-OHs having the hydroxyl group in position 2, and the same 7,8-dichloro substitution pattern in the nonphenolic ring. Increasing potencies were observed as the number of chlorine substituents surrounding the hydroxyl group increased from 0 to 2, with mean IC 50 values of 300 nm for 2-OH-7,8-DiCDD, 30 nm for 2-OH-3,7,8-TrCDD, and 4 nm for 2-OH-1,3,7,8-TeCDD (Table 1) . Figure 2 presents the concentration-inhibition relationships for PCDF-OHs with the hydroxyl group in the 2 or 3 position, para or meta to the furan oxygen, respectively. Again, the potency increased with increasing number of chlorine substituents adjacent to the hydroxyl group. Furthermore, 3-OH-PCDFs appeared to be slightly more potent inhibitors than 2-OH-PCDFs possessing comparable chlorine substitution patterns. Of all the PCDF-OHs tested, 3-OH-2,4,7,8,9-PeCDF was the most potent inhibitor of E2 sulfation. With a mean IC 50 value of as low as 0.18 nm, this compound has a more than 30-fold higher affinity for SULT1E1 than the natural substrate E2 ( Table 1) .
As demonstrated in Fig. 3 , all PBDE-OHs tested were relatively weak inhibitors of E2 sulfation by SULT1E1, with IC 50 values greater than 200 nm (Table 1) . Also, the one hydroxylated, polychlorodiphenylether tested, 2-OH-4,2Ј,4Ј-TrCDE, only inhibited SULT1E1 activity at micromolar concentrations (Table 1) . BPA did not affect E2 sulfation at concentrations less than 1 m, whereas its derivatives having halogens in all positions adjacent to the two hydroxyl groups, (Fig. 4 and Table 1 ).
The type of inhibition of E2 sulfation by the different PHAH-OHs was studied by Lineweaver-Burk analysis (Fig.  5) . Depending on the structure, different types of inhibition were observed. Addition of 2-OH-7,8-DiCDD (Fig. 5A ) or 2-OH-7,8-DiCDF (Fig. 5B ) changed the slope, but had little effect on the y-axis intercept of these plots, indicative of competitive inhibition. However, 2-OH-1,3,7,8-TeCDD (Fig.  5A ) and 3-OH-2,4,7,8,9-PeCDF (Fig. 5B ) affected both the slope and the y-axis intercept, and the plots converged at about the same point on the x-axis, indicating primarily noncompetitive inhibition by these potent inhibitors. The Lineweaver-Burk analyses of the effects of BPA and 3,5,3Ј,5Ј-TeCBPA (Fig. 5C ) and of 4-OH-3,5,2Ј,4Ј,6Ј-PeBDE (Fig. 5D ) indicate that these compounds inhibit E2 sulfation primarily in a noncompetitive manner. The K i values derived from these plots are in good agreement with the corresponding IC 50 Figure 6B shows that there was reasonable agreement between the results of the two methods regarding the sulfation of most compounds, although in several instances the BaSO 4 precipitation method significantly underestimated the formation of sulfated products in comparison with HPLC analysis. This was especially the case with sulfated compounds that were strongly retarded on the C 18 column, suggesting that relatively nonpolar sulfates are partially lost in the BaSO 4 precipitation method. Table 2 shows the results of the HPLC measurements of the sulfation of the various PHAH-OHs by SULT1E1 in comparison with the sulfation of these compounds by the human phenol sulfotransferase SULT1A1. We found that most PHAH-OHs tested in this study were sulfated by SULT1E1 as well as by SULT1A1 (Table 2) .
We also studied the inhibition of E2 sulfation by various PHAH-OHs using human liver cytosol as a source of native human SULT1E1. human liver cytosol, showing a strong correlation between the inhibitions of the recombinant and native enzymes (r ϭ 0.922). In general, human liver enzyme was less potently inhibited than recombinant human SULT1E1.
Discussion

Structure-activity relationship of SULT1E1 inhibition by PHAH-OHs
We previously showed that various PCB-OHs potently inhibit E2 sulfation by human SULT1E1 (30) . This finding suggested that endocrine-disrupting chemicals may act by increasing the bioavailability of hormones through inhibition of hormone-conjugating enzymes in target tissues (30, 42) . In this study we tested the effects of other classes of PHAH-OHs on E2 sulfation by SULT1E1. The results demonstrate that in all classes of PHAH-OHs tested, those with two adjacent halogen substituents around the OH group are the most potent inhibitors of E2 sulfation by SULT1E1, which is in agreement with the structure-activity relationship found for SULT1E1 inhibition by single ring halogenated phenols and hydroxylated PCBs (30) . A possible explanation for the increase in potency by adjacent halogen substitutions is the increased dissociation of the OH group. The potency of inhibitors with this substitution pattern decreases in the order PCDF-OH Ͼ PCDD-OH Ͼ BPA Ͼ PBDE-OH derivatives. The planar structures of PCDD-OHs and PCDF-OHs vs. the nonplanar structures of BPAs and PBDE-OHs may play a role in this, because the patterns for inhibition of SULT1E1 by PCB-OHs suggested preferred binding of coplanar compounds to the enzyme (30) . This finding fits with the primarily planar structure of the natural ligand E2. Recently, the crystal structure of the mouse estrogen sulfotransferase has been elucidated (43) . Mouse and human SULT1E1 show 77% amino acid sequence identity; both orthologous enzymes have K m values in the nanomolar range (25, 44) . The modeling of hydroxylated PHAHs in E2-binding sites of mouse SULT1E1 or human SULT1E1, when its crystal structure also becomes available, should further our understanding of the structural requirements for inhibition of SULT1E1.
Regarding the varying potencies of the different groups of (hydroxylated) PHAHs, it should be noted that levels of exposure are also different for the various PHAHs. The plasticizer BPA is commonly used in the food-packaging industry and in dentistry. Microgram amounts were found in the liquid from vegetable cans with plastic linings and in the saliva of patients with dental sealings (45) . TBBPA, TCBPA, and polybrominated diphenylethers are high production volume chemicals that are widely used in consumer electronics and many other products as flame retardants; the production volume of TBBPA in 1995 was higher than 50,000 tons/yr (46) . The background exposure of humans to PCDDs and PCDFs is much lower. Only trace levels (parts per trillion) of PCDDs and PCDFs have been detected in normal human blood and tissues (47) . However, as in our studies IC 50 values for some PCDD-OHs and PCDF-OHs were less than 1 nm, and 1 nm equals approximately 20 parts per trillion, the in vitro effects of the most potent PCDD-OHs and PCDF-OHs were observed at concentrations that may actually be in the same range that they are present in human tissues.
Depending on the structure, different types of inhibition were found with different PHAH-OHs. SULT1E1 is known to have two substrate-binding sites, the active site as well as an allosteric site (24, 48) . Binding of E2 to the latter site is thought to be largely responsible for the phenomenon of substrate inhibition that is observed at increasing E2 concentrations. The primarily competitive or noncompetitive nature by which the different PHAH-OHs inhibit the sulfation of E2 by SULT1E1 may thus be explained by their preferential affinity for the active or the allosteric site, respectively.
Sulfation of PHAH-OHs by SULT1E1 and SULT1A1
Estrogenic chemicals such as alkylphenols, diethylstilbestrol, and BPA have recently been shown to be substrates for human SULT1A1 (49, 50) . In this study we compared the sulfation of PHAH-OHs by SULT1E1 and SULT1A1. Most of the compounds tested were sulfated by SULT1E1 as well as by SULT1A1. It should be noted, however, that these incubations had to be performed with a limited PAPS concentration and excess substrate, which is very different from the conditions used to test the effects of PHAH-OHs on the sulfation of E2 by SULT1E1. Sulfation of the different PHAHOHs was tested at a single substrate concentration of 1 m, although the IC 50 and K i values for their inhibition of E2 sulfation ranged from less than 1 nm to more than 10 m. Therefore, the findings presented in Table 2 are not representative of the rate of sulfation of the different PHAH-OHs by SULT1E1 under the conditions where they were tested as inhibitors of E2 sulfation. Also, in view of the large variation in saturation of the low K m SULT1E1 and the high K m SULT1A1 at 1 m of the various substrates, the data reported in Table 2 are not representative of the substrate preferences of these isoenzymes at lower, more relevant PHAH-OH concentrations. The in vivo significance of sulfation of hydroxylated PHAHs in PHAH metabolism remains to be established.
Effects of PHAH-OHs on E2 sulfation by human liver cytosol
The effects of PHAH-OHs on E2 sulfation by SULT1E1 and by human liver cytosol were highly correlated. However, the relationship between the rates of E2 sulfation by the different enzyme preparations was nonlinear. Although SULT1E1 is the better enzyme for E2 sulfation, with a K m value of approximately 4 nm, SULT1A1 also catalyzes E2 sulfation, with a K m value of 2-5 m (51). The potencies of inhibition of SULT1E1 differ by orders of magnitude from those by which the different PHAH-OHs inhibit human SULT1A1 activity, which is characterized by apparent K i values in the micromolar range (33) . The nonlinear relationship between the rates of E2 sulfation by recombinant SULT1E1 and human liver cytosol in the presence of various PHAH-OHs may be explained by the presence of SULT1A1 in human liver. However, at nanomolar concentrations, E2 is predominantly sulfated in human liver by SULT1E1 (29) , suggesting that the nonlinear relationship is not due to significant sulfation of E2 in human liver by SULT1A1. A more likely explanation is suggested by our findings that the PHAH-OHs are sulfated by SULT1E1 as well as by SULT1A1. Therefore, compared with recombinant SULT1E1, larger amounts of the PHAHOHs will be metabolized in human liver cytosol, decreasing their inhibitory effects on native SULT1E1. An additional explanation may be that, compared with recombinant SULT1E1, human liver cytosol contains more proteins to which PHAH-OHs bind, diminishing their availability for native SULT1E1.
Concluding remarks
In this study we have demonstrated that E2 sulfation catalyzed by recombinant human SULT1E1 and that catalyzed by human liver sulfotransferase are both potently inhib- (20) . The most potent inhibitors have an even higher affinity for human SULT1E1 than its cognate substrate E2, which has a K m value of 4 nm for the enzyme (25) . Therefore, we hypothesize that part of the estrogenic activity of PHAHs is explained by an increase in E2 bioavailability through inhibition of human SULT1E1 by hydroxylated PHAH metabolites. Such a mechanism for the pseudoestrogenic activity of PHAH-OHs is particularly relevant for estrogenresponsive tissues that express SULT1E1, such as the endometrium, mammary gland, and testis (26 -28) . The effects of PHAH-OHs on the regulation of local estrogen levels in these tissues will depend on a variety of factors, such as the supply or local generation of the various PHAH metabolites, their potency in inhibiting SULT1E1, their rate of inactivation by SULT1E1 and other isoenzymes such as SULT1A1, their urinary or biliary excretion rates, and also on the reversal of the sulfation of E2 and the inhibitors by local estrogen sulfatase expression (52) .
PHAHs are known also to affect the thyroid hormone system. In laboratory animals, plasma T 4 is markedly decreased as a result of competitive binding of the hydroxylated metabolites to the plasma carrier transthyretin and induction of hepatic UDP-glucuronyltransferases by the PHAHs themselves (53) . PHAH-OHs have also been reported to inhibit the in vitro deiodination of thyroid hormone by the type I iodothyronine deiodinase as well as the sulfation of the hormone by human SULT1A1 (33) . During human fetal development, sulfation is an important pathway of thyroid hormone inactivation (54) . We have recently demonstrated that human SULT1E1 also efficiently catalyzes the sulfation of iodothyronines, among which are the prohormone T 4 and the active hormone T 3 (25) . Inhibition of SULT1E1 may thus also have thyroid hormone-disrupting effects during fetal development. Further studies should determine to what extent estrogen and possibly thyroid hormone levels are disrupted by hydroxylated PHAHs through inhibition of estrogen sulfotransferase.
